Guanidinoacetic Acid (GAA) supplementation with and without Creatine Monohydrate (CrM) on markers of cognitive function and health. Other
Conditions
Interventions
Participants will be randomized (using Stratified Randomization using sealed envelopes) into one of the three treatment groups listed below.
Treatment 1. Placebo (2 x 1 g maltodextrin + 5 g maltodext
Sponsors
The WoodNext Foundation
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Male or female between the ages of 18 and 65 years. 2. Participant has the ability to complete the study, comply with the study procedures, consume the investigational product daily for the duration of the study and provide voluntary written informed consent to participate in the study. 3. Participant is willing to refrain from alcohol intake and ingesting caffeinated foods and beverages for 48-hours prior to each testing session. 4. Participant is willing to not consume dietary supplements that may affect cognitive function during the study. 5. Participant is willing to comply and understand the cognitive function tests.
Exclusion criteria
Exclusion criteria: 1. Participant has a known vitamin B12/B6 or folate deficiency. 2. Participant has known homocystinuria. 3. Participant has high homocysteine levels. 4. Participant has a history of kidney disease requiring dialysis. 5. Participant has diagnosed cognitive impairment or neurological disease. 6. Participant is pregnant, breastfeeding, or wishing to become pregnant during the study. 7. Participant has uncontrolled heart disease, hypertension, diabetes, thyroid disease, cancer, neurological disease, or medically treated major psychological or depressive disorder that may affect the results of the study. 8. Participant has a known allergy to meat or fish, GAA, CrM, or maltodextrin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. A range of cognitive skills including processing speed, memory, attention, executive function, and visuoperceptual skills measured using the COMPASS Cognitive Function Test Battery at 0,6 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Body weight measured using a calibrated, digital scale at 0,6 weeks. 2. Resting hemodynamics (Heart Rate and Blood Pressure) measured using a sphygmomanometer at 0,6 weeks. 3. Body composition (%) measured using a calibrated DXA at 0,6 weeks. 4. Complete Blood Count (CBC) measured using automated analyzers from Clinical Pathology Laboratories (CPL) at 0,6 weeks. 5. Blood Chemistry Panel (Chem Panel) measured using automated analyzers from Clinical Pathology Laboratories (CPL) at 0,6 weeks. 6. Blood Lipids (Lipid Panel) measured using automated analyzers from Clinical Pathology Laboratories (CPL) at 0,6 weeks. 4. Homocysteine (Hcy) measured using automated analyzers from Clinical Pathology laboratories (CPL) at 0,6 weeks. 5. Menstrual experiences for females using the Menstrual Status Questionnaire at 0,6 weeks. 6. Menopause experiences for females using the Menopause Status Questionnaire at 0,6 weeks. 7. Adverse effects assessed using Side-Effects Assessment at 0,6 weeks. | — |
Countries
United States of America
Contacts
Public ContactChristopher Rasmussen
Outcome results
None listed